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Abstract 
Surgical trauma, which is inevitably associated with the surgical removal of 
cancer, has been reported to accelerate tumor metastasis. The close association of 
reactive oxygen species with the trauma and tumor metastasis supports the 
possibility of using antioxidants for the inhibition of metastasis. To inhibit 
surgical trauma-enhanced peritoneal dissemination, human catalase (hCAT) 
derivatives, i.e., hCAT-nona-arginine peptide (hCAT-R9) and hCAT-albumin 
binding peptide (hCAT-ABP), were designed to increase the retention time of the 





I-) derivatives showed significantly prolonged retention in 
the cavity than 
125
I-hCAT. Cauterization of the cecum of mice with a hot iron, an 
experimental model of surgical trauma, induced abdominal adhesions. In addition, 
cauterization followed by colon26 tumor cell inoculation increased lipid 
peroxidation in the cecum and mRNA expression of molecules associated with 
tissue repair/adhesion and inflammation in the peritoneum. hCAT derivatives 
significantly suppressed the increased mRNA expression. The cauterization also 
increased the number of tumor cells in the abdominal organs, and the number was 
significantly reduced by hCAT-R9 or hCAT-ABP. These results indicate that 
hCAT-R9 and hCAT-ABP, both of which have a long retention time in the 
peritoneal cavity, can be effective in inhibiting surgery-induced peritoneal 
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Much effort has been made to reduce the recurrence and metastasis of cancer after its surgical 
removal. However, recurrence and metastasis remain the major cause of cancer death [1]. 
Surgical removal, which is a pivotal treatment for most solid cancers including gastrointestinal 
carcinoma and ovarian carcinoma, has been suspected to facilitate cancer cell metastasis. This 
speculation has been supported by several animal studies, in which surgical stress aggravated 
tumor metastasis [2-5]. Although the mechanism whereby surgical stress enhances tumor 
metastasis is not fully understood, surgery-induced inflammation and subsequent wound healing 
have been considered to contribute to the facilitation of tumor metastasis [6,7]. In the processes 
of inflammation and wound healing, the expression of a variety of proinflammatory cytokines 
and growth factors is upregulated, which leads to increased production of extracellular matrix 
(ECM) components. Spilled tumor cells easily adhere to abdominal organs because of abundant 
ECM components and upregulated adhesion molecules. Then, the environment being rich with 
growth and angiogenic factors accelerates the proliferation of tumor cells and the formation of 
new blood vessels to form metastases. Thus, most, if not all, the steps of metastatic tumor 
growth, such as adhesion to the peritoneum and abdominal organs, proliferation and 
angiogenesis, are promoted by surgical trauma and the subsequent tissue repair. 
 Reactive oxygen species (ROS) are involved in both inflammation and tissue repair, and 
sublethal levels of ROS have been reported to aggravate tumor metastasis [8]. Therefore, 
eliminating ROS generated by surgical removal of a primary tumor could be an effective 
5 
 
approach to inhibiting postoperative peritoneal metastasis. Among ROS, hydrogen peroxide has 
the longest half-life and plays a role as a second messenger that directly activates several 
transcription factors, including hypoxia inducible factor-1 [9] and nuclear factor B [10].  
 Catalase is the enzyme that catalyzes the decomposition of hydrogen peroxide. Recent 
studies in experimental peritoneal metastasis mouse models have reported that tumor metastasis 
is efficiently inhibited by catalase derivatives with prolonged retention in the peritoneal cavity 
[11,12]. We have developed cytophilic derivatives of human catalase (hCAT) by fusing 
nona-arginine peptide (R9) or three repeats of arginine-glycine-aspartic acid and found that they 
were effective in inhibiting the adhesion of tumor cells to mouse aortic endothelial cells [13]. 
 These results suggest the possibility that hCAT derivatives are effective in inhibiting 
surgery-induced tissue adhesion and tumor metastasis. However, lack of appropriate 
experimental models of surgical trauma has made it difficult to evaluate this hypothesis. 
Therefore, in this study, a new surgery-induced abdominal adhesion model was developed in 
mice and used to evaluate the effects of hCAT derivatives on surgery-induced inflammation and 
peritoneal metastasis. In addition to hCAT and hCAT-R9, hCAT fused with an albumin binding 
peptide (ABP) [14] was designed as another novel derivative with a long retention in the 
peritoneal cavity through binding to exuded serum albumin. The properties of hCAT-ABP were 
initially examined and the effects of hCAT derivatives on surgery-induced peritoneal metastasis 
of tumor cells were investigated in our surgery-induced abdominal adhesion model.  
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Materials and methods 
Chemicals 
Roswell Park Memorial Institute (RPMI) 1640 medium and Hank’s balanced salt solution 
(HBSS) were obtained from Nissui Pharmaceutical (Tokyo, Japan). Fetal bovine serum (FBS) 
was obtained from GIBCO-Invitrogen (Carlsbad, CA, USA). Na
125
I aqueous solution in 0.1 M 
NaOH (NEZ033, 370MBq/ml) was purchased from Perkin-Elmer Life Sciences (Boston, MA, 
USA). Mouse and human serum albumins and bovine immunoglobulin G were purchased from 
Sigma-Aldrich Japan (Tokyo, Japan). All other chemicals were of the highest grade 
commercially available.  
 
Animals 
Male Institute for Cancer Research (ICR) mice (4-week-old), male BALB/c mice (4-week-old) 
and male C57BL/6 mice (4-week-old) were purchased from Japan SLC, Inc. (Shizuoka, Japan) 
and maintained on a standard food and water diet under conventional housing conditions. The 
protocols for the animal experiments were approved by the Animal Experimentation Committee 
of the Graduate School of Pharmaceutical Sciences of Kyoto University. 
 
Cell cultures 
Colon26/Luc, a clone of murine colon carcinoma colon26 that stably expresses firefly luciferase 
[11], were grown in RPMI 1640 medium supplemented with 10 % heat-inactivated FBS, 
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0.15 % NaHCO3, 100 units/ml penicillin and 100 g/ml streptomycin at 37 C in humidified air 
containing 5 % CO2. B16-BL6 cells, clones of murine melanoma, were grown as reported 
previously [11]. 
 
Preparation of human catalase derivatives 
hCAT and hCAT-R9 were obtained as reported previously [13]. hCAT-ABP was designed by 
replacing the C-terminal 11 amino acid residues (SHLAAREKANL) of hCAT with an ABP 
having the amino acid sequence GGGSQRLMEDICLPRWGCLWEDDF [14]. Double 
stranded oligonucleotide corresponding to ABP (forward sequence, 
5`-ggaggaggtagtcaaagattgatggaagacatttgcttgcccagatggggatgcttgtgggaagacgacttc-3`) was 
obtained by PCR-amplification with two oligonucleotides 
(5`-tccccgcgggaggaggtagtcaaagattgatggaagacatttgcttgcccagatgg-3` and 
5`-gctctagagctcagaagtcgtcttcccacaagcatccccatctgggcaagcaaatgtc-3`) purchased from 
GIBCO-Invitrogen. The PCR fragment was digested with SacII and XbaI and inserted into the 
SacII–SpeI site of hCAT expressing pNT40 vector to construct the hCAT-ABP expressing 
plasmid vector. hCAT-ABP was obtained similarly as hCAT and hCAT-R9 using a Pichia 
pastoris expression system. Recombinant catalase derivatives were purified as described 
previously [13], and the purity was identified by SDS-PAGE stained with Coomassie brilliant 
blue. The activity of hCAT, hCAT-R9 and hCAT-ABP was 33,800 to 37,900, 21,800 to 44,200 
and 9,000 to 68,300 units/mg protein, respectively [15]. The differences in the activity would be 
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due to the denaturation of the samples during the expression and/or purification processes. In 
vivo effects of hCAT derivatives on mRNA expression, intraabdominal adhesion and 
dissemination of tumor cells were evaluated using hCAT derivatives with high specific 
enzymatic activities: 33,800, 68,300 and 21,800-40,000 for hCAT, hCAT-ABP and hCAT-R9, 
respectively. The enzymes were stored in a 50 % glycerol solution at -20°C until required and 
they were stable under these conditions for at least for 12 months. The buffer was replaced with 
saline by ultrafiltration for animal studies. 
 
Measurement of circular dichroism 
Circular dichroism (CD) spectra were recorded on a JASCO-820-type spectropolarimeter 
(JASCO, Tokyo, Japan) at 4°C. For calculation of the mean residue ellipticity [θ], the molecular 
mass of the hCAT derivatives was assumed to be 240 kDa [16]. Far-UV (wavelength 200–250 
nm) CD spectra were recorded at a protein concentration of 0.2 mg/ml in a 50 % glycerol 
solution. 
 
Albumin affinity assay 
The binding affinity of hCAT derivatives to albumin or other proteins was determined as 
described previously [17]. Briefly, 2 g mouse serum albumin, human serum albumin or bovine 
immunoglobulin G was added to each well of 96-well plates at a volume of 100 l/well and 
incubated overnight at 4°C. The plates were blocked with phosphate buffered saline (PBS, pH 
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7.0) containing 0.5 % ovalbumin and 0.05 % Tween-20 for 60 min at room temperature. hCAT 
or hCAT-ABP serially diluted in PBS (pH 7.0) was added to the immobilized albumin at a 
volume of 100 l/well and incubated for 90 min at 25°C. Unbound hCAT derivatives were 
removed by washing wells with PBS containing 0.05 % Tween-20. Then, rabbit anti-catalase 
antibody was added to each well and incubated for 60 min at room temperature. Excess 
antibody was removed by washing, and goat anti-rabbit Fab'2-horseradish peroxidase (HRP) 
was added and incubated for 60 min at 25°C. Bound HRP was detected with a 
tetramethylbenzidine/hydrogen peroxide solution. After 20 min, the reaction was quenched by 
the addition of 1 M phosphoric acid. The absorbance at 450 nm was read at a reference 




hCAT derivatives were radiolabeled with 
125
I using the chloramine-T method [18]. A 90 l 
volume of sample solution (200 g/ml) was mixed with 10 l 0.5M phosphate buffer (pH 7.4) 
and 3 l [125I]NaI solution. Then, 10 l chloramine-T diluted in 0.1M phosphate buffer (pH 7.4) 
was added, and the mixture was vortexed for 30 sec and incubated for 10 min at room 
temperature. Finally, 10 l sodium metabisulfite solution (2.5 mM) was added and vortexed for 
30 sec. The solution was applied to a PD-10 column (GE healthcare, Tokyo, Japan) and eluted 
with 0.25 M phosphate buffer (pH 7.4) containing 0.2 % BSA. The eluent was collected in 
plastic tubes and the radioactivity was measured in a well-type NaI-scintillation counter 
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(ARC-500, Aloka, Tokyo, Japan). Appropriate fractions were taken and stored at -20°C until 
required for use.  
 
Tissue distribution of 
125
I-hCAT derivatives after intraperitoneal injection 
Each 
125
I-labeled hCAT derivative was injected intraperitoneally into male ICR mice at a dose 
of 0.5 mg/kg mouse. At appropriate intervals after injection, ascitic fluid was collected by 
injecting 5ml PBS. The peritoneum, liver, kidneys, and gastrointestinal tract were collected and 
washed with saline. The radioactivity of the tissue samples was counted as described above. 
 
Surgical trauma mouse model 
Male BALB/c mice or male C57BL/6 mice were anaesthetized with isoflurane. An 
approximately 10 mm long anterior midline incision was made through the abdominal wall and 
peritoneum. The cecum was gently isolated from the abdominal cavity and cauterized for 1 sec 
using an electrical soldering iron (Mypen alpha, HAKKO, Osaka, Japan). The cecum was 
returned to its normal position and the incision was closed with silk sutures. Administration of 
hCAT derivatives (500 units in 0.1 ml saline) was carried out immediately after closure by 
intraperitoneal injection. Five minutes after the surgery, 1×10
5
 colon26/Luc cells (BALB/c 
mice) or B16-BL6 cells (C57BL/6 mice) in 0.1 ml HBSS were inoculated into the cavity by 
intraperitoneal injection. 
 
Measurement of luciferase activity 
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At 3 days after inoculation of tumor cells, the peritoneum, liver, gastrointestinal tract, and 
greater omentum were removed. The tissues were homogenized in a lysis buffer (0.05 % 
TritonX-100, 0.1 M Tris, pH 7.8) followed by centrifugation at 13,000×g for 10 min. Then 10 l 
of the supernatant was mixed with 50 l luciferase assay buffer (Picagene, Toyo Ink, Tokyo, 
Japan) and the light produced was measured in a luminometer (Lumat LB 9507, EG&G 
Berthold, Bad Wildbad, Germany). 
 
mRNA quantification 
Total RNA was isolated using Sepasol RNAI super (Nacalai Tesque, Kyoto, Japan). The 
changes in the mRNA level of plasminogen activator inhibitor-1 (PAI-1), transforming growth 
factor-1 (TGF-1), intracellular adhesion molecule-1 (ICAM-1), vascular endothelium growth 
factor (VEGF) and tissue necrosis factor α (TNF-α) were examined using a real-time 
polymerase chain reaction (RT-PCR). Reverse transcription was performed using a ReverTra 
Ace
®
 qPCR RT Kit (TOYOBO, Osaka, Japan). For quantitative analysis of mRNA expression, 
RT-PCR was carried out with total RNA using a Light Cycler instrument (Roche Diagnostics, 
Basle, Switzerland). The oligonucleotide primers used for amplification were as follows: PAI-1, 
forward (5’-tcagcccttgcttgcctcat-3’) and reverse (5’-gcatagccagcaccgagga-3’); TGF-1, forward 
(5`-ttgcttcagctccacagaga-3`) and reverse (5`-tggttgtagagggcaaggac-3`); ICAM-1, forward 
(5`-gggaatgtcaccaggaat-3`) and reverse (5`-tcctgagccttctgtaacttg-3`); VEGF, forward 
(5`-ttcagagcggagaaagcatt-3`) and reverse (5`-gaggaggctccttcctgc-3`); TNF-α, forward 
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(5`-agccgatgggttgtaccttgtcta-3`) and reverse (5`-tgagatagcaaatcggctgacggt-3`); GAPDH, 
forward (5`-ctgccaagtatgatgacatcaacaa-3`) and reverse (5`-accaggaaatgagcttgaca-3`).   
Amplified products were detected online via intercalation of the fluorescent dye SYBR green 
(LightCycler-FastStart DNA Master SYBR Green I kit, Roche Diagnostics, Indianapolis, IN, 
USA). The mRNA expression of the target genes of interest was normalized to the mRNA level 
of GAPDH. 
 
Measurement of lipid peroxides 
 The isolated cecum was homogenized in 1.15 % KCl solution, centrifuged at 4,000×g, for 10 
min, and 200 l of the supernatant was mixed with 25 l 2,6-di-tert-butyl-4-methyl- 
phenol (5 mM in ethanol) and 200 l orthophosphoric acid (0.2 M). Then, 25 l  
2-thiobarbituric acid (TBA) reagent (0.11 M TBA in 0.1 M NaOH) was added, followed by 
vortexing for 10 sec to allow reaction with malondialdehyde (MDA). After incubation for 45 
min at 90 °C, thiobarbituric acid-reactive substances (TBARS) were extracted with 0.5 ml  
n-butanol. Then, the TBARS-derived fluorescence was measured in a multilabel counter 
(excitation at 530 nm, emission at 560 nm, Wallac 1420 ARVO MX-2; Perkin-Elmer Life 
Sciences Boston, MA, USA). Separately, the protein concentration of the supernatant was 
assayed using a BCA Protein Assay Kit (Pierce, Rockford, IL, USA). The TBARS values were 





Differences were statistically evaluated by one-way analysis of variance (ANOVA) followed by 
Fisher’s LSD for multiple comparisons and by Student’s t-test for two groups. P-values of less 




Properties of human catalase derivatives 
The properties of hCAT-R9 have already been reported [13]. The SDS-PAGE analysis showed a 
single band of about 60 kDa (Fig. 1A), which was comparable with the molecular weight of the 
hCAT monomer and consistent with the estimated molecular weight of hCAT-ABP (about 61 
kDa). Fig. 1B shows the far-UV CD-spectra of hCAT and hCAT-ABP. There was no significant 
difference in the spectra of hCAT and hCAT-ABP, indicating that the fusion of ABP to the 
C-terminal of human catalase hardly altered the secondary structure. hCAT-ABP was bound to 
immobilized mouse serum albumin, whereas hCAT was not (Fig. 1C). The binding of 
hCAT-ABP to the albumin was marked compared with the binding to human serum albumin or 
bovine immunoglobulin G (Fig. 1D). hCAT-R9 was also bound to immobilized mouse serum 
albumin, but its binding affinity was lower than that of hCAT-ABP. Its affinity for mouse serum 
albumin was comparable with that to human serum albumin or immunoglobulin G., suggesting 
that hCAT-R9 weakly and nonspecifically binds to negatively charged proteins (data not 
shown). 
 
Retention of human catalase derivatives in the abdomen 
The radioactivity in the ascitic fluid, peritoneum, greater omentum, liver, kidneys and 
gastrointestinal tract was summed and used as an indicator of the retention of 
125
I-hCAT 
derivatives in the abdomen after intraperitoneal injection. Fig. 2A shows the time course of 





derivatives. About 67 % of the radioactivity remained 1 hr after injection of 
125
I-hCAT-R9, 




I-hCAT-ABP. A high 
distribution of hCAT-derivatives was observed to the gastrointestinal tract and ascitic fluid (Fig. 
2B). At 8 hr after injection, significantly higher radioactivity was detected in the gastrointestinal 




I-hCAT-ABP than after 
125
I-hCAT (Fig. 2C). There 
was no significant radioactivity detected in the thyroid, suggesting that the radioactivity reflects 
the distribution of 
125
I-hCAT derivatives (data not shown). 
 
Abdominal changes induced by cauterization and tumor inoculation 
The cauterization induced intraabdominal adhesions among the cecum, peritoneum, 
gastrointestinal tract and adipose tissue (Supplemental figure A,B). To examine the 
overproduction of ROS by surgical treatment, the level of MDA, a marker for lipid peroxidation, 
in the cecum was measured on postoperative day 1. The MDA level of the surgery group was 
about 5 times higher than that in the non-surgery group (Fig. 3A). The mRNA expression levels 
of PAI-1, TGF-1, ICAM-1, VEGF and TNF- in the peritoneum were significantly increased 
by the surgical treatment (Fig. 3B), suggesting that inflammation and wound healing took place. 
Intraabdominal metastasis was markedly accelerated and widely disseminated by surgical 
trauma, especially in the peritoneum, the cauterized cecum and adhesion sites (Supplemental 
figure C-E). The total number of tumor cells increased about 12-fold on postoperative day 3 




Effect of hCAT derivatives on mRNA expression and intraabdominal adhesion 
Fig. 4 shows the mRNA expression levels in the peritoneum on postoperative day 1. The 
mRNA expression levels of PAI-1, TGF-1, ICAM-1, VEGF and TNF- in the peritoneum 
were significantly increased by the surgical treatment. The injection of any hCAT derivative at a 
dose of 500 units/mouse was effective in preventing the surgery-induced increase in the mRNA 
expression. No significant difference was observed among the groups treated with hCAT or 
hCAT derivatives. 
 
Inhibition of surgery-enhanced peritoneal dissemination by hCAT derivatives 
Fig. 5 shows the number of colon26/Luc cells in abdominal organs 3 days after inoculation. 
Cauterization of the cecum significantly increased the number of colon26/Luc cells in the 
cecum and the peritoneum. Administration of hCAT produced a slight but not significant 
reduction in the number, whereas hCAT-R9 or hCAT-ABP significantly reduced it to about 




Chemically modified catalase derivatives have been reported to have a therapeutic effect on 
such diseases [19-23]. Despite their usefulness, they are always associated with a potential risk 
of heterogeneity, reproducibility and reduced enzymatic activity. Instead, genetic modification 
techniques have been used to avoid these risks. In this study, P. pastoris, which has been used to 
express a number of proteins [24], was selected as the host to produce human catalase 
derivatives. 
 A previous study has reported that hCAT-R9 showed higher affinity for endothelial cells 
and a greater inhibitory effect on oxidative stress-accelerated adhesion of tumor cells in vitro 
than unmodified hCAT [13]. The prolonged retention of 
125
I-hCAT-R9 suggests that it can bind 
to the surface of abdominal organs after intraperitoneal injection. The surface of these organs is 
lined with mesothelial cells and an electrostatic interaction would be the reason for the long 
retention of hCAT-R9. When tissues are damaged, negatively charged basal membrane is 
exposed, so such a change would also become a site for hCAT-R9 binding.  
 Increasing the effective molecular size is another approach to prolonging the retention of 
hCAT in the abdominal cavity, because the systemic absorption from the cavity is a function of 
the size [25]. Serum albumin was selected as a partner because of its abundance and relatively 
large molecular size. Previous studies have reported that fusing the ABP to drugs with a short 
half-life improved the retention time in the blood [26]. In contrast to hCAT-R9, which exhibited 
a nonspecific interaction with the cell surface, hCAT-ABP could distribute to a larger area of the 
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abdominal cavity, where it would efficiently degrade ROS. This feature might explain why 
hCAT-ABP exhibited somewhat higher inhibitory effects than hCAT-R9, although the difference 
was not statistically significant. 
 Surgical trauma has been suggested to be an important aggravating factor for tumor 
metastasis [2-5,11], but its effects on metastasis have received little attention. We developed a 
surgery-enhanced peritoneal metastasis mouse model according to a recent publication [27]. 
The tissue damage and intraabdominal adhesions were reproducible when a fixed set of 
parameters were used. Therefore, this model appears to be a suitable preclinical model to 
investigate surgical trauma-induced tumor metastasis. 
 The cauterization induced a variety of changes in the abdominal organs that are typical of 
damaged tissues [6,7]. The increased mRNA expression of TNF-α, TGF-1 and VEGF 
suggested that the damage started to heal. These factors stimulate the synthesis of ECM and the 
expression of adhesion molecules, such as ICAM-1. On the other hand, the increased expression 
of PAI-1 could suppress the degradation of ECM components. Taken together, ECM 
components accumulate at the wound sites and contribute to tissue repair and remodeling. The 
present study clearly demonstrates that the surgery-induced changes significantly increase the 
metastatic growth of tumor cells. Therefore, it is strongly suggested that a postsurgical 
intraperitoneal environment is highly-favorable for detached and floating tumor cells to produce 
metastasis. 
 The inhibition of the mRNA expression by any hCAT derivative used (Fig. 4) indicates 
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that the scavenging hydrogen peroxide is a promising way of inhibiting the surgery-induced 
mRNA overexpression. Similar trends were observed in the number of colon26/Luc cells, but 
only hCAT-R9 and hCAT-ABP significantly reduced it (Fig. 5). We also obtained similar results 
using mouse melanoma B16-BL6 cells (Nishizaki et al., unpublished data). A possible reason 
for this discrepancy is the difference in the timing of these assays: 1 and 3 days after 
administration for mRNA expression and the number of tumor cells, respectively. hCAT is 
effective in inhibiting the mRNA expression at a very early time point but, because of its short 
retention time, it could be less effective in inhibiting metastatic tumor growth at later time points. 
In surgery-enhanced metastasis and recurrence, the most important process is the adhesion of 
tumor cells to the abdominal organs. Almost all spilled tumor cells in the cavity were reported to 
die within three days unless adhesion occurred. Therefore, hCAT derivatives can be considered 
to reduce the risk of cancer recurrence/metastasis, the major cause of cancer death. 
 There was high accumulation of 
125
I-hCAT derivatives in the GI tract (Figure 2B, C), 
whereas significant reduction in the number of colon26/Luc cells was observed in the 
peritoneum of the hCAT-ABP- or hCAT-R9-treated groups (Figure 5). This apparent 
discrepancy could be explained by the fact that the peritoneum is one of the typical organs 
where intraabdominal adhesions are formed (Supplemental figure). In addition, the cauterization 
could alter the distribution of hCAT derivatives. 
 In conclusion, hCAT-R9 or hCAT-ABP has been found effective in inhibiting the 
metastasis of colon26/Luc cells following intraperitoneal injection. No significant differences 
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were observed between hCAT-R9 and hCAT-ABP, suggesting that the retention time is 
important for the increased therapeutic effects of these derivatives. These results indicate that the 
newly developed hCAT derivatives are promising agents for inhibiting the surgical 
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hCAT, human catalase; hCAT-R9, human catalase fused with RRRRRRRRR; hCAT-ABP, 




I -labeled human catalase; 
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circular dichroism; PAI-1, plasminogen activator inhibitor-1; TGF-1, transforming growth 
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Fig.1: Characteristics of hCAT derivatives. 
(A) SDS-PAGE analysis of hCAT derivatives stained with Coomassie brilliant blue. Lanes 1 
and 4, Precision Protein Unstained Marker (Bio-Rad); lanes 2 and 5, crude hCAT (lane 2) and 
hCAT-ABP (lane 5); lanes 3 and 6; purified hCAT (lane 3) and hCAT-ABP (lane 6) using 
glutathione-Sepharose column. (B) Far-UV CD spectra of hCAT derivatives. The protein 
concentration was 0.2 mg/ml in 50 % glycerol buffer. (C) Binding of hCAT derivatives to 
immobilized mouse serum albumin. (D) Binding of hCAT-ABP to immobilized mouse serum 
albumin, human serum albumin or bovine immunoglobulin G. Key: MSA, mouse serum 
albumin; HSA, human serum albumin; IgG, bovine immunoglobulin G. 
 




(A) Time course of the total 
125
I-radioactivity in the abdominal organs and ascitic fluid of mice 







weight). Results are expressed as the mean ± SE of 4 mice. *P<0.05 compared with 
125
I-hCAT 
group at the same time point. (B, C) The tissue distribution of 
125
I-radioactivity at 1 hr (B) or 8 
hr (C) after intraperitoneal injection of 
125
I-hCAT derivatives. Results are expressed as the mean 






Fig.3: Effect of surgical trauma and intraperitoneal inoculation of colon26/Luc cells.  
(A) The level of MDA in the cecum on postoperative day 1. Results are expressed as the mean 
± SE of 4 mice. *P<0.05, compared with no treatment (NT) group. (B) The mRNA expression 
in the peritoneum on postoperative day 1. Results are expressed as the mean ± SE of 3 or 4 mice. 
*P<0.05 compared with the no treatment (NT) group; ✝P<0.05 compared with the 
colon26/Luc group; #P<0.05 compared with the other groups. (C) The total number of 
colon26/Luc cells in the abdominal organs on postoperative day 3. Results are expressed as the 
mean ± SE of 3 (non-surgery) or 5 (surgery) mice. *P<0.05 compared with the non-surgery 
group.  
 
Fig.4: Effect of hCAT derivatives on surgery-enhanced mRNA expression.   
The mRNA expression in the peritoneum on postoperative day 1. Results are expressed as the 
mean ± SE of 3 or 4 mice. *P<0.05 compared with the non-surgery group; ✝P<0.05 
compared with the colon26/Luc group; #P<0.05 compared with the other groups.  
 
Fig.5: Effect of hCAT derivatives on surgery-enhanced peritoneal dissemination.  
Colon26/Luc cells were inoculated into the peritoneal cavity (1105cells) after surgery. On 
postoperative day 3, the liver, omentum, peritoneum and gastrointestinal tract were isolated and 
the number of tumor cells was assayed. Results are expressed as the mean ± SE of 3 to 5 mice. 
*P<0.05, compared with the non-surgery group; #P<0.05, compared with the surgery, saline 
30 
 
group.
 
